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Background: Preclinical data suggest that miglustat could restore the function of the cystic ﬁbrosis transmembrane conductance regulator gene in
cystic ﬁbrosis cells.
Methods: Single-center, randomized, double-blind, placebo-controlled, crossover Phase II study in 11 patients (mean±SD age, 26.3±7.7 years)
homozygous for the F508del mutation received oral miglustat 200 mg t.i.d. or placebo for two 8-day cycles separated by a 14-day washout period.
The primary endpoint was the change in total chloride secretion (TCS) assessed by nasal potential difference.
Results: No statistically signiﬁcant changes in TCS, sweat chloride values or FEV1 were detected. Pharmacokinetic and safety were similar to those
observed in patients with other diseases exposed to miglustat.
Conclusions: There was no evidence of a treatment effect on any nasal potential difference variable. Further studies with miglustat need to ade-
quately address criteria for assessment of nasal potential difference.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Miglustat; Cystic ﬁbrosis; F508del; Efﬁcacy; Tolerability; Pharmacokinetics1. Introduction
Cystic fibrosis (CF) is the most common severe genetic dis-
ease in Caucasian populations. It is caused by mutations in the
CF transmembrane conductance regulator (CFTR) gene [1].
The encoded protein mainly acts as a cAMP-dependent chlo-
ride channel, but also regulates other membrane transporters
such as the epithelial sodium channel ENaC [2]. Ion transport
dysfunction in CF reduces the airway surface liquid volume
and results in repeated chronic infections and an exaggerated
inflammatory response.☆ Disclosure: The study data have been previously presented at the 33rd European
Cystic Fibrosis Conference, held 16–19 June 2010 in Valencia, Spain [abstract
n°75].
⁎ Corresponding author. Tel.: +32 2 7641939; fax: +32 2 7648906.
E-mail address: anissa.leonard@uclouvain.be (A. Leonard).
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doi:10.1016/j.jcf.2011.12.004More than 1700 mutations of the CFTR gene have been
identified. Approximately 70% of CF patients are homozygous
for the F508del mutation. The mutant protein resulting from the
F508del CFTR gene mutation is recognized as misfolded, be-
comes retained by the endoplasmic reticulum (ER) quality con-
trol, and is subsequently degraded within the ubiquitin-
proteasomal pathway (UPP) [3].
Miglustat (N-butyldeoxynojyrimicin, Zavesca®) is an imi-
nosugar currently marketed for adult patients with type 1
Gaucher disease for whom enzyme replacement therapy is
unsuitable/not a therapeutic option and for children and adults
with Niemann-Pick type C disease [4,5]. This compound is an
inhibitor of several enzymes, including α-glucosidase of the
ER. Recent in vitro studies showed that miglustat is able to cor-
rect impaired trafficking of F508del-CFTR protein [3,6,7].
Moreover, in vivo studies in F508del transgenic mice provided
evidence that nasal delivery of miglustat normalizes sodium
transport and CFTR-dependent chloride transport [8].by Elsevier B.V. All rights reserved.
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activity of calnexin, an important chaperone protein, on the in-
tracellular processing of F508del-CFTR protein [6]. Before it
interacts with calnexin, the F508del-CFTR protein must be gly-
cosylated, and miglustat may block this step due to its inhibito-
ry effect on ER α-glucosidase, thus preventing UPP-mediated
degradation of the misfolded protein [3].
This proof-of-concept study was designed to test the hypoth-
esis that miglustat may restore CFTR function in CF patients
homozygous for the F508del mutation.
2. Materials and methods
This was a single-center, double-blind, randomized,
placebo-controlled, two-period/two-treatment crossover, Phase
IIa proof-of-concept study. The study protocol was approved
by the local Ethics Committee, and study procedures were con-
ducted in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines. Informed written consent
was obtained from all patients and parents (when appropriate).
2.1. Patients
Patients enrolled in the study had a confirmed diagnosis of
CF as established by typical clinical features and abnormal
sweat test findings (sweat chloride N60 mmol/L). They were
aged 12 years or older, had clinically stable lung disease, and
carried the F508del mutation on both alleles of the CFTR
gene. Other criteria for eligibility included a forced expiratory
volume in 1 s (FEV1) of at least 25% of the predicted value
[9] and a blood oxygen saturation of at least 88% in room air.
Exclusion criteria included: any acute respiratory infection
within 2 weeks of screening; severe renal impairment; history
of neuropathy or clinically significant lactose intolerance; ac-
tive or passive smoking as assessed by exhaled CO measure-
ment (Smokelyzer®); pregnancy; breastfeeding and lack of
effective contraception in women.
2.2. Study design
Patients were randomized to one of two treatment sequences:
placebo/miglustat or miglustat/placebo. Miglustat or matching
placebo was administered orally at a dose of 200 mg t.i.d. forFig. 1. Study8 days. The two treatment periods were separated by a washout
period of at least 14 days (Fig. 1). There were no restrictions re-
garding concomitant medications, except that other investiga-
tional drugs and/or therapies (e.g., gene therapy) were not
allowed.
2.3. Endpoints
The primary pharmacodynamic endpoint was the change in
total chloride secretion (TCS) from baseline (pre-dose on Day
1) to the end-of-treatment (Day 8) of each treatment period.
TCS was quantified as the sum of nasal potential difference
(NPD) responses during consecutive perfusions of the nasal
mucosa with a chloride-free buffer with amiloride and a
chloride-free buffer with amiloride and isoproterenol. Response
of NPD to treatment was predefined as an on-treatment im-
provement in TCS of at least −5.0 mV from baseline, based
on previously published data [10].
Secondary endpoints included changes from baseline to the
end of each treatment period in: 1) basal NPD response; 2)
NPD response to a perfusion with amiloride; 3) NPD response
to a perfusion with a chloride-free solution with amiloride; 4)
NPD response to a perfusion with a chloride-free solution
with amiloride, isoproterenol, and ATP; 5) sweat chloride con-
centration (sweat production stimulated by pilocarpine ionto-
phoresis). The safety and tolerability of miglustat in patients
with CF were assessed by adverse event monitoring, hematolo-
gy, clinical chemistry, electrocardiograms (ECGs), vital signs,
and physical examinations.
Miglustat pharmacokinetics were also evaluated, and
changes in FEV1 were measured as an exploratory endpoint.
2.4. Measurement of NPD
Transepithelial NPD was measured according to a previous-
ly published method [11]. Briefly, NPD values were recorded
using a data memory high impedance voltmeter (Knick Porta-
mess®, Elektronische Messgeräte, Berlin, Germany) connected
to an Ag/AgCl exploring electrode built into a modified Foley
urinary catheter, which was inserted along the floor of the
nose (4–7 cm from the inferior turbinate). Only one nostril
was evaluated. A reference electrode was taped to a lightly
abraded skin area on the forearm.design.
Table 1
Demographics and characteristics of all 11 patients at the beginning of each
treatment period.
First period Second period
Age (y) 26.4±7.70
Gender (n)
Male 6
Female 5
Weight (kg) 64.1 9.6 63.3±10.3
FEV1 (% predicted) 80.7±18.7 77.8±21.3
Sweat chloride concentration (mmol/L) 111.9±11.8 110.6±10.8
Nasal potential difference
Basal PD (mV) −43.2±7.2 −43.7±7.1
Total chloride secretion (mV) −5.8±3.8 −4.7±3.4
Data are presented as mean (±SD) except gender (n).
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(Signa cream/Ringer's lactate; 1:1 v/v). The nasal catheter was
fixed at the site of the most stable negative voltage (PDmax)
and a phosphate-buffered Ringer's solution was perfused for
1 min. Subsequent, sequential perfusions were performed with:
1) a phosphate-buffered Ringer solution and 100 μM amiloride;
2) a chloride-free Ringer solution and 100 μM amiloride; 3) a
chloride-free Ringer solution with 100 μM amiloride and
10 μM isoproterenol; 4) a chloride-free Ringer solution with
100 μM amiloride, 10 μM isoproterenol, and 100 μM ATP. All
solutions were warmed to 36.9 °C. Prior to any NPD assessment,
the operator ensured that patients did not present any sign of
upper airway infection within 2 weeks before the study, and
that the concentration of exhaled carbon monoxide did not ex-
ceed 25 ppm.
NPD values were recorded once a stable negative voltage
value had been reached, which usually took approximately
5 min. Recorded data were analyzed using Paraly SW 105®
computer software. Separate, blinded assessments of tracings
were conducted at the end of the study by TL.
2.5. Bioanalytical and pharmacokinetic analyses
Trough miglustat plasma concentrations were collected on
Day 4 of both treatment periods. On Day 8, blood samples
were withdrawn just prior to the morning dose of study medica-
tion and at 1, 2.5, 4, 6, and 8 h after dosing. Plasma concentra-
tions of miglustat were determined using a validated LC-MS/
MS assay as recently described [12]. The calibration range
was 10–10,000 ng/mL, the coefficient of variation was
b13.5%, and assay inaccuracy was b6.4%.
Pharmacokinetic parameters were determined by model-
independent methods (WinNonlin Professional Version 4.0.1;
Pharsight, Mountain View, California, USA) whereby AUC
(area under the plasma concentration–time curve) was calculat-
ed using the linear trapezoidal method.
2.6. Statistics
Based on historical data obtained from healthy controls, a
sample size of 11 patients was predicted to have 90% power
to detect a difference in TCS of −5.0 mV, assuming a standard
deviation of 4.4 mV, using a paired t-test with a 0.05 two-sided
significance level [13]. Potential carry-over and period effects
were evaluated using mixed models. A two-sided paired t-test
was used to evaluate the null hypothesis that there would be
no difference between the effects of miglustat and placebo on
NPD; −5.0 mV was set as the required miglustat vs. placebo
difference to qualify the alternative hypothesis that the effects
of the two treatments differed. Statistical analyses of secondary
endpoints based on paired, two-sided treatment differences
were exploratory in nature.
3. Results
Eleven patients (mean±SD age, 26.4±7.7 years; six male,
five female) were enrolled, all of whom completed the study.Characteristics of the study group at the beginning of each
treatment period were similar (Table 1).3.1. NPD
There was no evidence of a treatment effect on any NPD
variable. Unexpectedly, TCS was equal to or less than −5 mV
at baseline in 6/11 patients during the miglustat treatment peri-
od and in 7/11 patients during the placebo period. There was a
mean±SD increase of 0.55±4.56 mV (95% CL −2.51, 3.60) in
TCS response from baseline to Day 8 with miglustat treatment,
and a mean decrease of −0.09±3.83 mV (95% CL −2.67, 2.48)
with placebo. The paired miglustat vs. placebo difference in
TCS was 0.64±6.25 mV (95% CL −3.56, 4.83; p=0.74)
[unadjusted t-test]. The paired difference of chloride secretion
between the two baseline tests was −0.5±2.6 mV, indicating
good within-subject reproducibility.
Table 2 shows changes in all pharmacodynamic endpoints
from baseline for each treatment period. No significant changes
from baseline were observed in any of these endpoints. Base-
line values obtained at the beginning of the miglustat and the
placebo period were not different (p=0.25; data not shown).3.2. Sweat chloride
As shown in Table 2 miglustat treatment did not modify
sweat electrolytes and intra-subject variability of sweat chloride
values was low during repeated testing in this study, with a
mean coefficient of variation of 5%.3.3. Pharmacokinetics
A total of 88 plasma samples were analyzed. Miglustat plas-
ma concentrations had reached steady-state conditions by Day
4. On Day 8, miglustat pharmacokinetics was characterized
by a tmax of 2.5 h, a Cmax of 2.5 μg/mL, and an AUC of
14 μg.h/mL. The mean plasma concentration‒time profile is
shown in Fig. 2.
Table 2
Changes from baseline in primary and secondary pharmacodynamic endpoints
at the end of the two treatment periods (all patients; n=11).
Miglustat
period
Placebo
period
p-value
Primary endpoint
Total chloride secretion (mV) −1.4±4.3 0.8±3.2 0.26
Secondary/exploratory endpoints
Basal NPD (mV) 2.2±7.0 −1.5±6.5 0.18
Amiloride response (mV) −1.0±10.5 −2.0±8.3 0.73
Sweat chloride concentration (mmol/L) −1.9±9.0 −1.5±8.4 0.97
FEV1 (% predicted) −1.4±4.6 −2.3±4.0 0.64
Data presented as mean±SD; p-values are from paired t-test (miglustat vs.
placebo).
Table 3
Summary of reported adverse events.
Miglustat Placebo
Total patients with at least one AE 11 (100%) 6 (54.5%)
Diarrhea 10 (91%) 4 (36%)
Abdominal discomfort 3 (27%) –
Headache 3 (27%) –
Abdominal pain 2 (18%) 1 (9%)
Aphtous stomatitis 1 (9%) –
Chills 1 (9%) –
Dizziness 1 (9%) –
Hypertension 1 (9%) –
Insomnia – 1 (9%)
Decreased appetite – 1 (9%)
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Adverse events were of mild or moderate intensity and no
patient discontinued study drug during the study. All patients
experienced at least one adverse event during miglustat treat-
ment and 6/11 experienced adverse events on placebo. The
most frequent adverse event was diarrhea, occurring in 10/11
patients (91%) on miglustat treatment and 4/11 patients (36%)
on placebo treatment (Table 3). There were no clinically signif-
icant findings in relation to laboratory variables or ECG abnor-
malities. There were no deaths or SAEs reported during the
study. No clinically relevant changes were observed in vital
signs, except in one patient who experienced worsening of
pre-existing hypertension during miglustat treatment.
4. Discussion
This is only the second placebo-controlled trial conducted in
the past decade to investigate the possible improvement of
F508del-CFTR function using a pharmacological agent [14].
In this study, no evidence was obtained of a treatment effectFig. 2. Plasma concentration–time profile of miglustat on Day 8 in cystic fibro-
sis patients treated with miglustat 200 mg t.i.d. (all patients; n=11). Data points
represent mean (±SD).on any NPD variable. However, NPD findings from this
study are difficult to interpret due to poor intra-individual re-
peatability of TCS measurements and higher than expected
baseline values for TCS, offering little or no room for
improvement.
NPD is the only in vivo functional surrogate marker of CFTR
function at the level of the human respiratory tract, and TCS is a
key disease variable as it primarily reflects CFTR chloride chan-
nel activity. Accordingly, all published early-phase clinical tri-
als of medications aimed at restoring mutant CFTR function
have postulated that efficacy should be demonstrated by a sig-
nificant shift in TCS towards the normal range; ten studies of
this sort have been published over the past 11 years [10,15–
23]. Still, although physiologically meaningful, NPD is not a
very robust efficacy index and is prone to error.
The range of usual TCS values in CF patients is narrow
(roughly −10 mV to +10 mV) and mean TCS is close to
zero, precluding calculation of a coefficient of variation for
the parameter. Further, the within-subject variability of TCS
has been shown to be larger than its between-subject variability,
which indicates low repeatability [24]. Data concerning this
variability are limited, have been obtained using different
setups with subtle technical differences, and have most often
been derived from comparisons of tracings obtained in two nos-
trils during a single session. Operator skill, a number of techni-
cal details, the influence of modifier genes, and the effects of
concurrent medications have all been identified as potential
sources of NPD variability during multicenter clinical trials
[24]. Our NPD measurements were performed by one skilled
operator, which should have lowered within-subject variability.
However, our values were recorded in a single nostril, while av-
eraging measurements from two nostrils could have reduced
variability [18]. In addition, the most recent equipment for mea-
suring NPD was not available at the time of the study; newer
equipment has been shown to improve NPD tracing stability
and to reduce artifact frequency by 75% [25].
NPD measurements have long been used in our center for di-
agnostic purposes. Reference values and cut-offs of −30 mV
for PDmax and −10 mV for TCS were established in 2002
[11,26]. Such values are identical to those recently suggested
by Middleton and House [27]. However, it should be noted
that in clinical trials, a significant response of TCS to treatment
is usually defined as a change of at least −5 mV [19].
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treatment period and the placebo treatment period felt within
the CF range and were identical to those recently reported in
76 patients homozygous for the F508del mutation (−43 mV)
[27]. The mean coefficient of variation for PDmax was 16%.
The most puzzling finding in this study was the unexpected
residual chloride secretion observed at baseline in half of the
enrolled patients. Three out of 22 baseline measurements
yielded TCS ≤−10 mV, and a further six yielded values be-
tween −6 mV and −9 mV. This was not expected as published
TCS values in classic CF patients are typically around 0; means
range from 4 mV [28] to −3 mV in our center [29]. It is likely
that some methodological factor(s) contributed to this range.
For instance, the use of agar catheters shifted TCS in CF pa-
tients to less positive values, with a mean difference of 2 mV
as compared with the perfusion method [25]. So-called ‘chlo-
ride secretors’ with TCS values more negative than −5 mV
have been reported in approximately 10% of cases by several
skilled operators investigating groups of subjects, completely
or mostly homozygous for the F508del mutation, [27,29]. In
one multicenter study, 15/75 (20%) F508del homozygous pa-
tients were categorized as chloride secretors, with similar pro-
portions observed across three hospitals [29].
Methodological factors and poor reproducibility of TCS
measurements are also likely involved to some extent, and re-
peating measurements using the most recent setup and protocol
could help in this respect. Environmental factors such as con-
comitant medications could also be involved. Several symp-
tomatic medications often prescribed in CF might influence
ion transport across the nasal epithelia, but this is seldom eval-
uated. In the present study, azithromycin, inhaled salmeterol,
inhaled acetylcysteine, and nasal steroids were prescribed to
10, 11, 4, and 5 out of the 11 enrolled patients, respectively.
Fulfillment of inclusion criteria in this study did not confirm the
absence of bias. As do most investigators, we chose to select reli-
able candidates in order to minimize patient dropout. A compas-
sionate bias may also have led us to focus on patients who were
in relatively good health to avoid subjecting more ill patients to
a demanding protocol. As a result, the study group included
young adults with high FEV1. Furthermore, when assessed by lin-
ear regression using the best value of each quarter, the mean annu-
al decline in FEV1 over the past 10 years was −1.2% (i.e., patients
improved over time). Even considering the mean decline of
−0.4% over 8 years recently reported in this clinic [30], it would
appear that the patients enrolled were doing especially well.
Although miglustat treatment did not modify sweat electro-
lytes this finding does not preclude the effectiveness of the
drug because, at this point in time, the extent to which an
agent capable of rescuing chloride secretion by respiratory epi-
thelial cells also influences absorptive sweat duct epithelium re-
mains unclear.
The pharmacokinetics and tolerability of miglustat in this
cohort of CF patients were similar to those observed in patients
with other conditions [4]. These findings are of potential impor-
tance, given that the pharmacokinetics of a number of drugs are
altered in patients with CF, and that patients with pancreatic in-
sufficiency are especially prone to gastrointestinal disturbances.In conclusion, no miglustat effect was detected in the present
study. A further, larger study of oral miglustat in CF patients
homozygous for the F508del mutation that incorporates the cur-
rent NPD setup and a standardized protocol would help to clar-
ify possible technical limitations of the NPD test as it was
performed. Pre-enrolment screening of NPD measurements
would be recommended in order to exclude chloride secretors,
and caution should be taken to avoid selection biases that
might exclude less healthy patients. Blinded over-reading,
employing predefined criteria for low-quality tracings would
be recommended to allow exclusion of data, if necessary. In ad-
dition, in light of recent data a longer duration of miglustat
treatment and possible combination therapy with a potentiator
compound could be considered [31].
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